Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study

Am J Ophthalmol. 2007 Apr;143(4):705-7. doi: 10.1016/j.ajo.2006.11.040. Epub 2006 Dec 21.


Purpose: To evaluate the protein osteopontin (OPN) as a potential new marker for screening and detection of metastatic uveal melanoma.

Design: Prospective, clinical study.

Methods: Twenty-eight plasma samples of 27 patients with uveal melanoma were analyzed, and the OPN plasma levels were quantified. Eight of these patients showed liver metastasis. As a control, we measured OPN levels in eight healthy, age-matched individuals.

Results: The median plasma concentration of OPN in patients with melanoma without metastasis was 46.78 ng/ml (range, 14.5 to 118.67 ng/ml). In contrast, increased median levels of OPN of 170.72 ng/ml (range, 87.37 to 375.54 ng/ml, P <.001) were seen in eight patients with proven metastatic disease. Healthy patients without uveal melanoma showed a median plasma concentration of OPN of 54.6 ng/ml (range, 38.23 to 71.21 ng/ml).

Conclusion: The protein OPN seems to be a promising tumor marker for detecting metastatic disease in patients with uveal melanoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Liver Neoplasms / blood*
  • Liver Neoplasms / secondary
  • Male
  • Melanoma / blood*
  • Melanoma / secondary
  • Middle Aged
  • Osteopontin / blood*
  • Pilot Projects
  • Prospective Studies
  • Uveal Neoplasms / blood*
  • Uveal Neoplasms / pathology


  • Biomarkers, Tumor
  • Osteopontin